Caremark Issues Statement on Questcor's (QCOR) Acthar Gel

January 31, 2013 11:53 AM EST Send to a Friend
Questcor Pharmacueticals, Inc. (NASDAQ: QCOR) shares are flat as CVS Caremark (NYSE: CVS)

H.P. Acthar Gel (repository corticotrophin injection) was approved for marketing in 1952. Since that time Acthar gel has shown to produce positive therapeutic outcomes in disease states such as infantile spasms, nephrotic syndrome, and multiple sclerosis.

Effectiveness of H.P. Acthar Gel (ACTH) for treatment of infantile spasms was shown in a single blinded clinical trial in which patients received either a 2 week course of treatment with H.P. Acthar Gel or prednisone. The study compared the number of patients in each group who were treatment responders. Thirteen of 15 patients (86.7%) responded to Acthar Gel as compared to 4 of 14 patients (28.6%) given prednisone. Afterwards the prednisone nonresponders were given the choice to receive H.P. Acthar Gel treatment. Seven of 8 patients (87.5%) responded to H.P Acthar Gel after not responding to prednisone. Studies have also shown that patients with nephrotic syndrome have had successful outcomes with Acthar Gel after failing other therapies. The Bomback, et al study demonstrated that ACTH gel produced remission rates approaching 80%. Also the Rauen, et al study concluded ACTH treatment produced a lasting remission with few side effects. Ponticelli, et al performed a study which compared the combination therapy of methylprednisolone with a cytotoxic agent and monotherapy of ACTH. The findings showed monotherapy ACTH was as effective for nephrotic patients as the combination of methylprednisolone and a cytotoxic agent.

Filippini, et al produced a study of the use of H.P. Acthar Gel for multiple sclerosis in two randomized, double-blind trials. ACTH showed a protective effect against progression and stabilization of the disease. Thompson, et al’s trial showed marked improvement in patients with acute relapse of MS after the use of ACTH. The study from Hauser, et al determined that combination therapy with cyclophosphamide and ACTH stabilized patients’ progressive MS.

Approved indications that are not supported by the clinical literature have been excluded from prior approval criteria.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Comments

Try BCBS Horizon or UHC Oxford
Investor on 2013-01-31 17:54:30
Mark as Spam | Reply to this comment

They will cover it all. Buy their insurance instead of Caremark and their policies are dated effective 2/26/2013 and 1/1/2013 respectively. NOW THAT'S NEW NEWS not 7 months old. QCOR stock should soar!!!

Manipulator
Investor on 2013-01-31 17:27:57
Mark as Spam | Reply to this comment

This Clinical Rational Statement was made by Caremark on 6/11/2012. Why are you trying to make it look like new news? Very unprofessional in my opinion for you not to mention that this was published back in June of 2012 and has not changed.


Add Your Comment